cefamandole | 1205565-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: cefamandole
• 英文别名: Cefamandol；(6R)-7t-((R)-2-hydroxy-2-phenyl-acetylamino)-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid；7-{[hydroxy(phenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid；7-[(2-hydroxy-2-phenylacetyl)amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
• CAS: 1205565-14-5
• 化学式: C₁₈H₁₈N₆O₅S₂
• mdl: MFCD02114247
• 分子量: 462.51
• InChiKey: OLVCFLKTBJRLHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  201
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  cefamandole 生成 Cephamandole sodium
  参考文献：
  名称：

  POL. J. CHEM., 64,(1990) N-6, C. 387-388

  摘要：

  DOI：
• 作为产物：
  描述：

  (2-Hydroxy-2-phenyl-acetylsulfanyl)-acetic acid ethyl ester 、 3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 、 trimethylsilyl 7-amino-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 生成 cefamandole
  参考文献：
  名称：

  POL. J. CHEM., 64,(1990) N-6, C. 387-388

  摘要：

  DOI：

文献信息

• An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant
  申请人：INTERx RESEARCH CORPORATION

  公开号：EP0036534A1

  公开（公告）日：1981-09-30

  A drug form is provided for increasing the oral absorption of β-lactam antibiotics such as the penicillins, cephalosporins and related chemical species by the oral administration of said β-lactam antibiotics in a suitable pharmaceutically accepted excipient to which has been added a hydroxy aryl or hydroxy aralkyl acid or salt, amide or ester thereof. The hydroxyaryl or hydroxyaralkyl acid or salt, amide or ester thereof is present in the drug form in quantities sufficient to be effective in enhancing the rate of oral absorption of the β-lactam antibiotic.

  本发明提供了一种药物形式，通过将β-内酰胺类抗生素口服于适当的药学上可接受的赋形剂中，并在赋形剂中加入羟基芳基或羟基芳烷基酸或其盐、酰胺或酯，从而增加β-内酰胺类抗生素如青霉素类、头孢菌素类及相关化学物质的口服吸收。羟基芳基或羟基烷基酸或其盐、酰胺或酯在药物形式中的含量足以有效提高 β-内酰胺类抗生素的口服吸收率。
• A rectally administered suppository comprising a drug and an adjuvant
  申请人：Merck & Co., Inc.

  公开号：EP0031561A2

  公开（公告）日：1981-07-08

  A drug form for enhancing the rate of absorption of a rectally administered drug from the rectal compartment into the blood stream of a warm blooded animal. The drug form comprises a therapeutically effective dosage amount of a selected drug of the type which is capable of being absorbed into the blood stream from the rectal compartment and hydroxy aryl or hydroxy aralkyl acids or salts, amides or esters thereof, the hydroxy aryl or hydroxy aralkyl acids or salts, amides or esters thereof being present in the drug form in a sufficient amount to be effective in enhancing the drug absorption rate, when rectally administering the drug form to warm blooded animals.

  一种药物形式，用于提高直肠给药药物从直肠进入温血动物血流的吸收率。该药物剂型包括治疗有效剂量的可从直肠吸收进入血流的精选药物和羟基芳基或羟基芳烷基酸或其盐、酰胺或酯类，其中羟基芳基或羟基芳烷基酸或其盐、酰胺或酯类在药物剂型中的含量足以在给温血动物直肠给药时有效提高药物吸收率。
• Rectally administrable suppository comprising a drug and an adjuvant
  申请人：Merck & Co., Inc.

  公开号：EP0083032B1

  公开（公告）日：1989-09-20
• Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase
  申请人：Yale University

  公开号：US20150272939A1

  公开（公告）日：2015-10-01

  The present invention includes a novel high-throughput screen capable of identifying compounds that inhibit JARID1B demethylase activity or JARID1A demethylase activity. The present invention further includes novel inhibitors of JARID1B demethylase activity and/or JARID1A demethylase activity, and methods using the same.
• US4406896A
  申请人：——

  公开号：US4406896A

  公开（公告）日：1983-09-27